Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph Jankovic

Showing results (441-450 of 574) with videos related to

Pageof 58
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society|October 22, 2008
A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristicsC Warren Olanow, Robert A Hauser, Joseph Jankovic, et al.
Neurology|January 31, 2024
Efficacy and Safety of DaxibotulinumtoxinA for Injection in Cervical Dystonia: ASPEN-1 Phase 3 Randomized Controlled TrialCynthia L Comella, Joseph Jankovic, Robert A Hauser, et al.
JAMA Neurology|December 13, 2016
Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical TrialAnthony H V Schapira, Susan H Fox, Robert A Hauser, et al.
Toxins|May 26, 2023
Neutralizing Antibody Formation with OnabotulinumtoxinA (BOTOX<sup>®</sup>) Treatment from Global Registration Studies across Multiple Indications: A Meta-AnalysisJoseph Jankovic, Jean Carruthers, Markus Naumann, et al.
American Journal of Clinical Pathology|March 18, 2008
CSF multianalyte profile distinguishes Alzheimer and Parkinson diseasesJing Zhang, Izabela Sokal, Elaine R Peskind, et al.
Parkinsonism & Related Disorders|April 17, 2007
A founding LRRK2 haplotype shared by Tunisian, US, European and Middle Eastern families with Parkinson's diseaseL Warren, R Gibson, L Ishihara, et al.
European Journal of Neurology|March 17, 2021
Worldwide barriers to genetic testing for movement disordersEmilia M Gatto, Ruth H Walker, Claudio Gonzalez, et al.
Ebiomedicine|October 2, 2022
Whole genome sequencing identifies candidate genes for familial essential tremor and reveals biological pathways implicated in essential tremor aetiologyLorraine N Clark, Yizhe Gao, Gao T Wang, et al.
Parkinsonism & Related Disorders|August 18, 2019
Hypertension and progressive supranuclear palsySoniya V Rabadia, Irene Litvan, Jorge Juncos, et al.
Clinical Neuropharmacology|June 4, 2008
A study of chorea after tetrabenazine withdrawal in patients with Huntington diseaseSamuel Frank, William Ondo, Stanley Fahn, et al.
Pageof 58

Showing results (441-450 of 574) with videos related to

Sort By:
Pageof 58
Movement Disorders : Official Journal of the Movement Disorder Society|October 22, 2008
A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristicsC Warren Olanow, Robert A Hauser, Joseph Jankovic, et al.
Neurology|January 31, 2024
Efficacy and Safety of DaxibotulinumtoxinA for Injection in Cervical Dystonia: ASPEN-1 Phase 3 Randomized Controlled TrialCynthia L Comella, Joseph Jankovic, Robert A Hauser, et al.
JAMA Neurology|December 13, 2016
Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical TrialAnthony H V Schapira, Susan H Fox, Robert A Hauser, et al.
Toxins|May 26, 2023
Neutralizing Antibody Formation with OnabotulinumtoxinA (BOTOX<sup>®</sup>) Treatment from Global Registration Studies across Multiple Indications: A Meta-AnalysisJoseph Jankovic, Jean Carruthers, Markus Naumann, et al.
American Journal of Clinical Pathology|March 18, 2008
CSF multianalyte profile distinguishes Alzheimer and Parkinson diseasesJing Zhang, Izabela Sokal, Elaine R Peskind, et al.
Parkinsonism & Related Disorders|April 17, 2007
A founding LRRK2 haplotype shared by Tunisian, US, European and Middle Eastern families with Parkinson's diseaseL Warren, R Gibson, L Ishihara, et al.
European Journal of Neurology|March 17, 2021
Worldwide barriers to genetic testing for movement disordersEmilia M Gatto, Ruth H Walker, Claudio Gonzalez, et al.
Ebiomedicine|October 2, 2022
Whole genome sequencing identifies candidate genes for familial essential tremor and reveals biological pathways implicated in essential tremor aetiologyLorraine N Clark, Yizhe Gao, Gao T Wang, et al.
Parkinsonism & Related Disorders|August 18, 2019
Hypertension and progressive supranuclear palsySoniya V Rabadia, Irene Litvan, Jorge Juncos, et al.
Clinical Neuropharmacology|June 4, 2008
A study of chorea after tetrabenazine withdrawal in patients with Huntington diseaseSamuel Frank, William Ondo, Stanley Fahn, et al.
Pageof 58